JPWO2005063984A1 - 遺伝子発現を抑制する二本鎖ｒｎａ - Google Patents

遺伝子発現を抑制する二本鎖ｒｎａ Download PDF

Info

Publication number
JPWO2005063984A1
JPWO2005063984A1 JP2005516695A JP2005516695A JPWO2005063984A1 JP WO2005063984 A1 JPWO2005063984 A1 JP WO2005063984A1 JP 2005516695 A JP2005516695 A JP 2005516695A JP 2005516695 A JP2005516695 A JP 2005516695A JP WO2005063984 A1 JPWO2005063984 A1 JP WO2005063984A1
Authority
JP
Japan
Prior art keywords
rna
sequence
vegf receptor
expression
small interfering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005516695A
Other languages
English (en)
Japanese (ja)
Inventor
澁谷　正史
正史 澁谷
直幸 矢花
直幸 矢花
Original Assignee
澁谷　正史
正史 澁谷
直幸 矢花
直幸 矢花
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 澁谷　正史, 正史 澁谷, 直幸 矢花, 直幸 矢花 filed Critical 澁谷　正史
Publication of JPWO2005063984A1 publication Critical patent/JPWO2005063984A1/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2005516695A 2003-12-30 2004-12-27 遺伝子発現を抑制する二本鎖ｒｎａ Pending JPWO2005063984A1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53338903P 2003-12-30 2003-12-30
US60/533,389 2003-12-30
PCT/JP2004/019556 WO2005063984A1 (fr) 2003-12-30 2004-12-27 Adn double brin inhibant l'expression genique

Publications (1)

Publication Number Publication Date
JPWO2005063984A1 true JPWO2005063984A1 (ja) 2007-07-19

Family

ID=34738860

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005516695A Pending JPWO2005063984A1 (ja) 2003-12-30 2004-12-27 遺伝子発現を抑制する二本鎖ｒｎａ

Country Status (2)

Country Link
JP (1) JPWO2005063984A1 (fr)
WO (1) WO2005063984A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018348048B2 (en) 2017-10-10 2021-08-26 Nantbio, Inc. Modified EC7 cells having low toxicity to viral production payloads

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070910A2 (fr) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Inhibition induite par interference d'arn du facteur de croissance endothelial vasculaire et expression genetique du recepteur de facteur de croissance endothelial vasculaire au moyen d'acides nucleiques interferents courts (sina)
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis

Also Published As

Publication number Publication date
WO2005063984A1 (fr) 2005-07-14

Similar Documents

Publication Publication Date Title
Wang et al. CircUbe3a from M2 macrophage-derived small extracellular vesicles mediates myocardial fibrosis after acute myocardial infarction
US9198981B2 (en) Modulation of angiogenesis
US20120277144A1 (en) Novel compounds for modulating neovascularisation and methods of treatment using these compounds
US20210139997A1 (en) Treatment of angiogenesis disorders
Guan et al. MicroRNA-18a-5p administration suppresses retinal neovascularization by targeting FGF1 and HIF1A
US9649379B2 (en) Pharmaceutical composition and pharmaceutical kit for the treatment of hepatocellular carcinoma
US20110123534A1 (en) Novel compounds for modulating neovascularisation and methods of treatment using these compounds
JP2007530431A (ja) 膵臓癌を治療するための組成物および方法
Chen et al. EphA1 receptor silencing by small interfering RNA has antiangiogenic and antitumor efficacy in hepatocellular carcinoma
Zhang et al. SUMO protease SENP1 acts as a ceRNA for TGFBR2 and thus activates TGFBR2/Smad signaling responsible for LPS-induced sepsis
JP2015173601A (ja) がん幹細胞の増殖抑制物質のスクリーニング方法
JP2014506888A (ja) アデニンヌクレオチドトランスケータ２ｍＲＮＡ発現を減少させて乳房癌を治療する方法
WO2013091293A1 (fr) Médicament qui est associé au gène nlk humain et son utilisation
Luo et al. Tsp-1+ microglia attenuate retinal neovascularization by maintaining the expression of Smad3 in endothelial cells through exosomes with decreased miR-27a-5p
US9051568B2 (en) Anti-sense microrna expression vectors
JPWO2005063984A1 (ja) 遺伝子発現を抑制する二本鎖ｒｎａ
WO2008142198A2 (fr) Procédé pour inhiber ou stimuler l'angiogenèse dans un sujet
KR101713886B1 (ko) ＰＲＫ２를 표적으로 하는 Ｃ형 간염 바이러스 치료제 ｓｉＲＮＡ
US11788091B2 (en) Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth
JP6778848B2 (ja) 抗がん剤
US20180008641A1 (en) Use of MicroRNA 375 in Augmenting Stem Cell Based and Endogenous Ischemic Tissue Repair
US20220193111A1 (en) Method of Treatment
RATIH STUDY OF MAMMAGLOBIN 1 AS A REGULATOR IN TRASTUZUMAB RESISTANT CELLS’AGGRESSIVENESS
WO2024076781A1 (fr) Polynucléotides pour le silençage d'une variante de transcription 1 d'un facteur d'assemblage pour des microtubules spindle et leurs applications
JP4480125B2 (ja) ｓｉＲＮＡを用いたヒト血管内皮増殖因子の発現の強い抑制。